Good Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Good Therapeutics's estimated annual revenue is currently $620k per year.
- Good Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Good Therapeutics has 4 Employees.
- Good Therapeutics grew their employee count by 0% last year.
Good Therapeutics's People
Name | Title | Email/Phone |
---|
Good Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Good Therapeutics?
We are developing a new technology for self-regulating drugs that will provide a therapeutic activity when and where it is needed.
keywords:N/AN/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Good Therapeutics News
2022-04-20 - Global Osteoarthritis Therapeutics Market Growth Opportunity ...
Increased prevalence of this disease is expected to augur well for the market in the near future. The global osteoarthritis therapeutics...
2022-04-19 - Monoclonal Antibody Therapeutics Market Witnesses Massive ...
Furthermore, the therapy is a good replacement for cancer drugs and chemotherapy. All these factors help in propelling the growth of the...
2022-04-19 - Bill Gates' plan to develop lifesaving drugs faster
A therapeutic drug could save tens of thousands of lives as a vaccine ... According to Gates, "[w]ith good therapeutics, the risk of severe...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 4 | -33% | N/A |
#2 | $0.1M | 4 | -33% | $2.5M |
#3 | $0.3M | 4 | N/A | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.1M | 4 | 0% | $2.5M |